Wisconsin Alumni Research Foundation

Katarzyna M Barycka

Hector Floyd Deluca

Lori A Plum

Margaret Clagett-Dame

Rafal R Sicinski

Rafal Barycki

Katarzyna Plonska-Ocypa

Izabela K Sibilska

Julia B Zella

Izabela Sibliska

Hector F Deluca

Katarzyna Plonskaocypa

This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin Dand pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.

1-desoxy-2-methylene-19-nor-vitamin D analogs and their uses

This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin Dand (20R)-25-hydroxy-2-methylene-19-nor-vitamin D, as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. Although these compounds have relatively low calcemic activities they may also be useful in the treatment of bone diseases due to their ability to act as prodrugs in vivo.

2-methylene-19-nor-vitamin D analogs and their uses

The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form.

Methods and compositions for phosphate binding

Growing community of inventors

Madison, WI, United States of America

Katarzyna M Barycka